Genprex granted Japanese and EU patents for Reqorsa Gene Therapy

Genprex (GNPX) announced that the Japanese Patent Office has issued a favorable Appeal Decision to grant a patent claiming the use of Reqorsa Gene Therapy in combination with PD-L1 antibodies to treat cancer. Also, the European Patent Office has issued a Decision to Grant relating to a patent for the combination of Reqorsa and PD-1 antibodies to treat cancer. Genprex maintains an exclusive license to these patents. The company already holds granted patents for the use of Reqorsa in combination with PD-L1 antibodies in the U.S. and Korea, with a pending grant in Australia. Genprex also holds granted patents for the combination of Reqorsa and PD-1 antibodies in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore and Europe.